The content on this site is intended for healthcare professionals only

For the latest ecancer COVID-19 resources, click on this link

Breast

Prostate & urology

Lung & pleura

Colorectal & gastro

Melanoma & skin

Head & neck

Ovary & gynaecology

+ -

Aspirin protects against colorectal cancer, says international clinical trial

ECCO 15 - ESMO 34

20 - 24 Sep 2009

Published: 21 Sep 2009

Views: 13057

Rating:

Save

Professor John Burn, Institute of Human Genetics, Newcastle University, UK

Aspirin protects against colorectal cancer, says international clinical trial. Press conference from ECCO 15 ESMO 34, Berlin.

Categories:
Colorectal & gastro

Related Videos

RAGNAR study evidences efficacy and safety of erdafitinib in patients with advan...

Dr Yohann Loriot - Institut Gustave Roussy, Villejuif, France

RAGNAR study evidences efficacy and safety of erdafitinib in patients with advanced FGFR+ malignancies ( Dr Yohann Loriot - Institut Gustave Roussy, Villejuif, France )

ASCO 2022: Highlights and analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2022: Highlights and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal strom...

Dr César Serrano - Vall d'Hebron Institute of Oncology, Barcelona, Spain

ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal stromal tumour ( Dr César Serrano - Vall d'Hebron Institute of Oncology, Barcelona, Spain )

FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-ty...

Dr Chiara Cremolini - University of Pisa, Pisa, Italy

FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-type mCC ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )

Comment: Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

Dr Chiara Cremolini - University of Pisa, Pisa, Italy

Comment: Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )

Comment:Trifluridine/tipiracil, bevacizumab + trifluridine/tipiracil provides be...

Dr Cathy Eng- Vanderbilt-Ingram Cancer Center, Nashville, USA

Comment:Trifluridine/tipiracil, bevacizumab + trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients ( Dr Cathy Eng- Vanderbilt-Ingram Cancer Center, Nashville, USA )

Trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil provides bene...

Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan

Trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients ( Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan )

Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-defic...

Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York

Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer ( Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York )

Circulating tumour DNA analysis can help identify the need for adjuvant therapy ...

Dr Jeanne Tie - The Peter MacCallum Cancer Centre, Melbourne, Australia

Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer ( Dr Jeanne Tie - The Peter MacCallum Cancer Centre, Melbourne, Australia )

More from ecancer